Our goal is to identify Corporate Supporters that share our mission to find a cure for Niemann-Pick Type C disease through outreach, education, and philanthropy. If you are interested in becoming a Corporate Supporter, please contact Sean Kassen at skassen@nd.edu.
Mallinckrodt Pharmaceuticals is a pharmaceutical company focused on their mission: Managing Complexity. Improving Lives. They provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. They are currently developing VTS-270, a potential treatment for NPC disease.
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases.
They harness the amplification of Heat-Shock Proteins (or HSP’s) in order to develop and commercialize novel therapeutics for serious diseases including lysosomal storage diseases and neuromuscular degenerative diseases.
Orphazyme is developing arimoclomol as a treatment for NPC disease.